An Alzheimer’s patient on what was lost when Biogen shut down its trial, and what may be gained again
ADOBE
Debby Rosenkrantz, a 66-year-old volunteer in one of Biogen’s studies, says she is looking forward to reversing what she said was “a major loss.”
.png)
No hay comentarios:
Publicar un comentario